You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

confirmed MMRD or MSI-H IHC

Showing 1 - 25 of 6,757
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
Oct 7, 2022

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)

Recruiting
  • Colon Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 26, 2023

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

Not yet recruiting
  • Gastric
  • Colorectal Adenocarcinoma
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 1, 2023

Endometrial Cancer Trial (Anlotinib + Camrelizumab)

Not yet recruiting
  • Endometrial Cancer
  • Anlotinib + Camrelizumab
  • (no location specified)
Sep 26, 2022

Pancreatic Cancer Trial (Pembrolizumab, Olaparib)

Not yet recruiting
  • Pancreatic Cancer
  • (no location specified)
Oct 21, 2021

A Retrospective Study on Multiple Classifier Endometrial Cancer

Recruiting
  • Uterine Cancer
  • Observation only
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Jul 27, 2023

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Tumor Vaccine Benefit for Gliomas

    Recruiting
    • Glioma
    • DC vaccine
    • Shanghai, China
      Huashan Hospital，Fudan University
    Sep 12, 2023

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

    Completed
    • Recurrent/Metastatic Gastric Cancer
    • Nivolumab, Paclitaxel
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Sep 9, 2022

    Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

    Recruiting
    • Serplulimab,Gastric Cancer, Adjuvant Therapy
    • Shanghai, China
      Zhang Zizhen
    Mar 3, 2023

    Head and Neck Tumors, MSI-H Cancer, Melanoma Trial (Tiragolumab and atezolizumab)

    Not yet recruiting
    • Head and Neck Neoplasms
    • +2 more
    • Tiragolumab and atezolizumab
    • (no location specified)
    Aug 1, 2022

    Colorectal Tumors Trial in China (Pembrolizumab, Oxaliplatin, Leucovorin)

    Recruiting
    • Colorectal Neoplasms
    • Pembrolizumab
    • +6 more
    • Beijing, Beijing, China
    • +21 more
    Jan 25, 2023

    Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))

    Recruiting
    • Colorectal Neoplasms
    • Microsatellite Instability
    • temozolomide (induction),
    • pembrolizumab (treatment)
    • Milano, Italy
    • +3 more
    Sep 28, 2022

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

    Not yet recruiting
    • Colorectal Cancer
    • +3 more
    • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
    • ZhengZhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jun 18, 2023

    MSI-H, PD-1 Immunotherapy, Gastric Cancer Trial in Shanghai (SOX, XELOX, Observation)

    Not yet recruiting
    • MSI-H
    • +3 more
    • Shanghai, China
      Dazhi Xu
    Jul 20, 2022

    Registry Study in MSI/dMMR Solid Tumors

    Not yet recruiting
    • DMMR Cancer
    • +2 more
      • (no location specified)
      Aug 21, 2023

      MSI-H Solid Malignant Tumor Trial in China (HLX10)

      Recruiting
      • MSI-H Solid Malignant Tumor
      • Hefei, Anhui, China
      • +32 more
      Oct 26, 2022

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

      Recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • PD-1 inhibitor
      • Guangzhou, China
        Sun Yat-sen University Cancer Center
      Aug 9, 2023

      Toripalimab, Radiation Trial in Hangzhou (Toripalimab, CRT, SCRT)

      Recruiting
      • Toripalimab
      • Radiation
      • Hangzhou, Zhejiang, China
        Zhengjiang Cancer Hospital
      Dec 29, 2022

      MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

      Not yet recruiting
      • MSI-H/dMMR Gastroesophageal-junction Cancer
      • MSI-H/dMMR Gastric Cancer
      • (no location specified)
      Oct 30, 2023